Neuroactive steroid levels are altered in several experimental models of peripheral neuropathy, and on this basis, they have been proposed as protective agents. For the first time, the levels of these molecules were assessed here in sterol regulatory element binding protein -1c knock-out male mice (i.e., an experimental model of peripheral neuropathy) and compared with observations in wild type animals. The levels of neuroactive steroids have been evaluated by liquid chromatography-tandem mass spectrometry in plasma and sciatic nerve at 2 and 10 months of age and these analyses were implemented analyzing the gene expression of crucial steroidogenic enzymes in sciatic nerve. Data obtained at 2 months of age showed high levels of pregnenolone in sciatic nerve, associated with low levels of its first metabolite, progesterone, and further metabolites (i.e., 5a-pregnane-3,20-dione and 5a-pregnan-3b-ol-20-one). High levels of testosterone and 17b-estradiol were also observed. At 10 months of age, the neuroactive steroid profile showed some differences. Indeed, low levels of pregnenolone and high levels of 5a-pregnan-3a-ol-20-one and 5a-pregnan-3b-ol-20-one were observed. The analysis of the gene expression of steroidogenic enzymes considered here generally followed these changes. Interestingly, the levels of pregnenolone and progesterone were unmodified in plasma suggesting a specific effect of sterol regulatory element binding protein-1c on neurosteroidogenesis. Because this peripheral neuropathy is due to altered fatty acid biosynthesis, data reported here support the belief that the cross-talk between this biosynthetic pathway and neuroactive steroids may represent a possible therapeutic strategy for peripheral neuropathy.
Sterol regulatory element binding protein-1c (SREBP-1c) is a transcription factor of the basic helix-loop-helix-leucine zipper family that preferentially controls the synthesis of fatty acids (FA) and triglycerides (Liang et al. 2002) . Fatty acids represent, together with cholesterol, the most abundant myelin lipids of the peripheral nervous system (PNS) (Garbay et al. 2000) . However, while the role of cholesterol metabolism is well understood (Saher and Stumpf 2015) , the specific contribution of FA synthesis remains to be elucidated. To this end, we have recently explored the lack of the key lipogenic transcription factor SREBP-1c on peripheral myelin compartment . Data we obtained show that SREBP-1c knock-out (KO) mice, at 2 months of age, display a neuropathic phenotype (i.e., impairment of thermal and mechanical nociceptive threshold, subtle abnormalities of small unmyelinated C fibers) that results in hypermyelination of small-caliber fibers because of changes in myelin periodicity at 10 months of age . In addition, these animals showed a decreased expression of biosynthesis genes as well as altered levels of fatty acids, such as palmitic, stearic, oleic, and linoleic acids, in sciatic nerve . Altogether, these results indicate that impairment of FA synthesis lead to the development of peripheral neuropathy. In this context, it is important to highlight the role of neuroactive steroids. These latter are molecules acting in the nervous system including steroids produced by the nervous system (i.e., neurosteroids) and hormonal steroids coming from classical steroidogenic tissues (i.e., gonads and adrenal glands) . In particular, neuroactive steroids have been proposed as protective agents for different kinds of peripheral neuropathy, such as those because of aging, physical injury, chemotherapy, and diabetes (Melcangi et al. 2011; Giatti et al. 2015) . PNS is not only a target for the action of neuroactive steroids but is also able to synthesize and metabolize them. Indeed, Schwann cells (i.e., cells forming peripheral myelin) express the machinery of the first step of steroidogenesis, such as the enzyme cytochrome P450 side chain cleavage (P450scc), responsible for the conversion of cholesterol into pregnenolone (PREG) (Zhu and Glaser 2008; Olbrich et al. 2013) . In addition, Schwann cells as well as dorsal root ganglia express steroidogenic enzymes such as 3b-hydroxysteroid dehydrogenase, which converts PREG into progesterone (PROG) (Chan et al. 2000; Schumacher et al. 2001; Coirini et al. 2003; RodriguezWaitkus et al. 2003 ) and 5a-reductase (5a-R) type 1, which converts PROG and testosterone (T) into 5a-pregnane-3,20-dione (5a-DHP) and 5a-androstan-17b-ol-3-one (5a-DHT), respectively (Melcangi et al. 2011; Giatti et al. 2015) . Moreover, 5a-DHP and 5a-DHT are then further metabolized by the action of 3a-or 3b-hydroxysteroid oxidoreductase (3a-or 3b-HSOR) (Melcangi et al. 2011; Giatti et al. 2015) . In particular, 5a-DHP is converted in 5a-pregnan-3a-ol-20-one (3a,5a-THP) or in 5a-pregnan-3b-ol-20-one (3b,5a-THP), while 5a-DHT is converted in 5a-androstane-3a, 17b-diol (3a-diol) or in 5a-androstane-3b,17b-diol (3b-diol). T is also converted into 17b-estradiol (17b-E) by the action of aromatase. In agreement, with the neurosterodogenic capacity of PNS, altered levels of neuroactive steroids were reported in different experimental models of peripheral neuropathy (Melcangi et al. 2014 (Melcangi et al. , 2016 Giatti et al. 2015) . Interestingly, a link between neuroactive steroids and FA synthesis in the PNS has also been reported. Indeed, activation of liver X receptors exerts important neuroprotective effects in diabetic peripheral neuropathy induced by streptozotocin, restoring the altered SREBP-1c function in sciatic nerve, myelin fatty acids, as well as neuroactive steroids levels (Cermenati et al. 2010 (Cermenati et al. , 2012 . In addition, in the same experimental model, treatment with 5a-DHP or 3a-diol exerts neuroprotective effects modulating myelin lipid profile in the sciatic nerve. Indeed, both neuroactive steroids were able to normalize the levels of stearic and oleic acids, as well as of SREBP-1c and expression of enzymes involved in the de novo lipogenic pathways . All these effects resulted in a reduction in the myelin alterations (i.e., myelin infoldings) observed in the sciatic nerve of diabetic animals .
On the basis of these results, levels of neuroactive steroids were evaluated in plasma as well as in sciatic nerve of SREBP-1c KO mice at 2 and 10 months of age and compared with levels observed in wild type (WT) littermate animals. These analyses were implemented analyzing in sciatic nerve the gene expression of crucial steroidogenic enzymes, such as P450scc, 5a-R and 3a-HSOR. Our hypothesis is that the lack of the lipogenic transcription factor sterol regulatory element binding protein-1c (SREBP-1c) affects the level of neuroprotective molecules, such as neuroactive steroids, in sciatic nerve during early (2 months of age) and late (10 months of age) phases of peripheral neuropathy development occurring in SREBP-1c KO mice.
Materials and methods
PREG, PROG, 5a-DHP, 3a,5a-THP, 3b,5a-THP, T, 5a-DHT, 3a-diol, 3b-diol, dehydroepiandrosterone (DHEA), and 17b-E were purchased from Sigma-Aldrich, Milan, Italy. 17b-Estradiol-2,3,4-13 C 3 (1 ng/sample), C 2 (10 ng/sample), and PROG-2,3,4-13 C 3 (0.4 ng/sample) were used as internal standards (Sigma-Aldrich). Samples were prepared with a solid phase extraction (SPE) cartridges (Thermo Scientific TM HyperSep TM C18, San Jose, CA, USA). All solvents and reagents were liquid chromatography-tandem mass spectrometry (LC-MS) grade (CARLO ERBA Reagents, Milano, Italy). Animals SREBP-1c KO mice, an animal model of reduced de novo lipogenesis, were purchased from The Jackson Laboratories, Bar Harbor, ME, USA (B6;129S6-Srebf1tm1Jdh, stock number: 004365) and were bred to generate a colony of wild type, heterozygous and homozygous mice. Animals were maintained in standard cages (four animals per cage), and were exposed to light/ dark cycles of 12 : 12 h at constant temperature (23°C) with food and water available ad libitum. The genotyping was performed, according to The Jackson Laboratory instructions, with the GoTaq Green Master Mix (Promega, Milan, Italy) . The experiments were conduct with either 2-or 10-month-old male mice. 
Study design
Special care was taken to minimize animal suffering and to reduce the number of animals used, which is the minimum required for statistical accuracy. In order to minimize the number of animals used in the experiments, we applied a power analysis. Using G power software, we applied F-test ANOVA analysis (repeated measures between factors) by setting the effect size (f) at 0.75 (calculated with the same software in our experience with previous experiments), the alpha error probability at 0.05, the power of the test ≥ 80%, and we obtained five animals per group.
Once genotyped, after weaning, the mice were blinded and arbitrarily assigned to the four experimental groups (2-month-old animals-group wild type and group SREBP-1c KO based on genotype; 10-month-old animals-group wild type and group SREBP-1c KO based on genotype). Specifically, a person not familiar with the experiment chose, among several male wild type mice, 10 animals to form the wild type group and the same was done for the SREBP-1cKO. The same person further arbitrarily asssigned mice to 2-month-old wild type and SREBP-1cKO groups (five animals per genotype) and to 10-month-old wild type and SREBP1cKO groups (five animals per genotype). However, at the end of process, the weight of the mice was not statistically different between all the groups.
Inclusion and exclusion criteria
Because of the possible sex-related differences due to steroids fluctuation in females, we decided to perform these experiments only with male mice.
For 2-month-old mice: SREBP-1cKO male mice must show impairment of thermal and mechanical nociceptive threshold, and no effects on nerve conduction velocity (early sign of peripheral neuropathy) compared to relative age littermates.
For 10-month-old mice: SREBP-1cKO male mice must show impairment of thermal and mechanical nociceptive threshold, and nerve conduction velocity (late sign of peripheral neuropathy) compared to relative age littermates.
Quantification of neuroactive steroids by LC-MS/MS
Neuroactive steroids were quantified in sciatic nerve and plasma from wild type and SREBP-1c KO mice at 2 and 10 months of age. Sciatic nerves (15 mg per animals) from the two experimental groups were prepared according to (Caruso et al. 2013) . Briefly, tissue samples were added with internals standards, homogenized in 2 mL of methanol (MeOH)/acetic acid (99 : 1 v/v) using a tissue lyser (Qiagen, Milan, Italy). After an overnight extraction at 4°C, samples were centrifuged at 15 294 g for 5 min and the pellet was extracted twice with 1 mL of MeOH/acetic acid (99 : 1 v/v). The organic phases were combined and dried with a gentle stream of nitrogen in a 40°C water bath. The samples were resuspended with 3 mL of MeOH/H 2 0 (10 : 90 v/v) and passed through SPE cartridges, previously activated with MeOH (5 mL) and MeOH: H 2 O 1 : 9 v/v (5 mL), the steroids were eluted in MeOH, concentrated and transferred in autosampler vials before the LC-MS/MS analysis. Plasma samples (250 lL per animals), added with internal standards, were first extracted with acetonitrile, the organic residues were resuspended with 3 mL of MeOH/H 2 0 (10 : 90 v/v) and passed through SPE cartridges; the steroids were eluted in MeOH, concentrated and transferred in autosampler vials before the LC-MS/MS analysis. Quantitative analysis was performed on the basis of calibration curves daily prepared and analyzed.
The LC-MS/MS was carried out using a linear ion trap-mass spectrometer with an APCI source working in positive ion mode (LTQ, ThermoElectron Co., San Jose, CA, USA) equipped with a Surveyor liquid chromatography (LC) Pump Plus and a Surveyor Autosampler Plus (ThermoElectron Co.). The mass spectrometer (MS) was employed in tandem mode (MS⁄MS) using helium as collision gas. The LC mobile phases were (A) H 2 O/0.1% formic acid and (B) MeOH/0.1% formic acid. The gradient (flow rate 0.5 mL/min) was as follows: T 0 70%A, T 1.5 70%A, T 2 55%A, T 3 55%A, T 35 36%A, T 40 25%A, T 41 1%A, T 45 1%A, T 45.2 70%A, and T 55 70%A. The split valve was set at 0-6.99 min to waste, 6.99-43.93 min to source, and 43.93-55 to waste. The Hypersil Gold column (100 9 3 mm, 3 lm; ThermoElectron Co) was maintained at 40°C. The LC analysis was divided into three time windows to improve the sensitivity: in the first one (14.5-17.9 min) 17b-E, T and DHEA are eluted, and we used 13 C-estradiol as internal standard; in the second one (18-29 min) PROG, 5a-DHT, 3a-and 3b-diol are eluted and 13 C-progesterone is used as internal standard, in the last window (32-46 min), the quantification of PREG, 5a-DHP, 3a,5a-THP, and 3b,5a-THP was achieved using 13 C-pregnenolone (Caruso et al. 2010b) . The validation of the method and transition used were previously described (Caruso et al. 2010a (Caruso et al. , 2013 .
Quantitative real-time PCR
For the gene expression analysis, total mRNAs were extracted from wild type and Srebp-1c knockout sciatic nerves using the Nucleospin RNA II kit (Macherey-Nagel, Duren, Germany). The gene expression profile of the enzymes involved in steroidogenesis was done with a TaqMan qRT-PCR instrument (CFX96 real-time system; Bio-Rad Laboratories, Segrate, Italy) using the iScriptTM one-step RT-PCR kit for probes (Bio-Rad Laboratories). Samples were run in 384-well formats in triplicate as multiplex reactions and the 36B4 was used as housekeeping gene for all the analyses.
Statistical analysis
Data obtained from the two experimental groups were analyzed by two-way ANOVA, with genotype and age as two independent variables, followed by Bonferroni post-test. All statistical analyses were performed in PRISM version 5 (GraphPad, La Jolla, CA, USA) considering a p < 0.05 as statistically significant (the number of animals is reported in the figure legends).
Results
The levels of PREG, DHEA, PROG and its derivatives (i.e., 5a-DHP, 3a,5a-THP and 3b,5a-THP), T and its derivatives (5a-DHT, 3a-diol, 3b-diol and 17b-E) were assessed by LC-MS/MS in sciatic nerve and plasma of SREBP-1c KO mice and WT animals at two different ages (i.e., 2 and 10 months). As reported in Fig. 1 , two-way ANOVA analysis revealed in sciatic nerve a significant effect of genotype on the levels of PREG (p < 0.001) as well as of its further metabolites, such as PROG (p < 0.001), 5a-DHP (p < 0.001), and 3a,5a-THP (p < 0.05). In case of PREG levels, a significant effect of age (p < 0.001) and interaction (p < 0.001) was also observed. In particular, Bonferroni post-test indicated in sciatic nerve of SREBP-1c KO that PREG levels at 2 months of age are significantly higher in comparison to those observed in WT animals and significantly lower at 10 months. At 2 months of age, Bonferroni post-test also revealed that the levels of PROG, 5a-DHP, and 3b,5a-THP are significantly lower than those found in WT animals. At 10 months of age, the levels of PROG are significantly lower and those of 3a,5a-THP and 3b,5a-THP, significantly higher compared to WT mice. As reported in Fig. 2 , among DHEA and its further metabolites (i.e., T, 5a-DHT, 3a-diol, 3b-diol, and 17b-E), only T levels analysis revealed a significant effect of genotype (p < 0.05), age (p < 0.05), and interaction between the two parameters (p < 0.01), while the levels of 17b-E were significant only for the interaction between genotype and age (p < 0.01). At 2 months of age, Bonferroni post-test showed that T levels were significantly higher in sciatic nerve of SREBP-1c KO in comparison to what was observed in WT animals. The same effect was observed on the levels of 17b-E. Fig. 1 Pregnenolone (PREG), progesterone (PROG) and its derivatives in sciatic nerve of wild type (WT) and sterol regulatory-binding protein-1c (SREBP-1c) knock-out (KO) mice at 2 and 10 months of age. Data (n = 5 for each experimental group) are expressed as pg/mg AE SEM. The effects of age, genotype, and their interaction have been analyzed using the two-way ANOVA: *p < 0.05; **p < 0.01, and ***p < 0.001 (see table) , followed by Bonferroni post-test: *p < 0.05; **p < 0.01, and ***p < 0.001 versus WT (see histogram).
The situation is quite different in the plasma. Indeed, twoway ANOVA analysis revealed a significant effect of genotype on the levels of PREG (p < 0.05), but no effect of age and their interaction (Fig. 3) . PROG levels were not significantly different by two-way ANOVA and Bonferroni post-test, while at 2 months of age, T levels were significantly higher in plasma of SREBP-1c KO than in WT animals only by Bonferroni post-test.
As reported in Fig. 4 two-way ANOVA analysis revealed in the sciatic nerve a significant effect of age (p < 0.05) on the gene expression of P450scc (i.e., enzyme converting cholesterol into PREG), 5a-R (i.e., enzyme converting PROG and T into 5a-DHP and 5a-DHT, respectively), and 3a-HSOR (i.e., enzyme converting 5a-DHP and 5a-DHT into 3a,5a-THP and 3a-diol, respectively). In case of the enzyme 5a-R, two-way ANOVA analysis also revealed a significant effect of genotype (p < 0.01) but not significant interaction, while the enzyme 3a-HSOR revealed significant effect of genotype (p < 0.05) as well as interaction (p < 0.05). In particular, Bonferroni post-test revealed that at 2 months of age, the Fig. 2 Dehydroepiandrosterone (DHEA), T and its derivatives in sciatic nerve of wild type (WT) and sterol regulatory-binding protein-1c (SREBP-1c) knock-out (KO) mice at 2 and 10 months of age. Data (n = 5 for each experimental group) are expressed as pg/mg AE SEM. The effects of age, genotype, and their interaction have been analyzed using the two-way ANOVA: *p < 0.05 and **p < 0.01 (see table) , followed by Bonferroni post-test: *p < 0.05 and **p < 0.01 versus WT (see histogram).
gene expression of P450scc was significantly higher in sciatic nerve of SREBP-1c KO than in WT animals. At 10 months of age, the gene expression of 5a-R and 3a-HSOR was significantly higher in the sciatic nerve of SREBP-1c KO than in WT animals.
Discussion
As we have recently demonstrated, lack of the key lipogenic transcription factor SREBP-1c favors the development of peripheral neuropathy . Data here reported indicate for the first time that, according to what has been observed in other experimental models of acquired (i.e., aging process, physical injury, diabetes) and hereditary (i.e., CMT1A) peripheral neuropathy (Melcangi et al. 2014 (Melcangi et al. , 2016 Giatti et al. 2015) , SREBP-1c KO mice also show altered levels of neuroactive steroids in sciatic nerve. In particular, as here reported, changes in the levels of PREG (i.e., the first neuroactive steroid formed from cholesterol) occurred. Interestingly, the effect is different depending on the age of animals considering that it parallels the severity of peripheral neuropathy. Indeed, at 2 months of age, we observed that SREBP-1c KO mice showed significantly higher levels of this neuroactive steroid in comparison to what was reported in WT animals, while at 10 months of age, lower levels of PREG was detected. The gene expression of the enzyme converting cholesterol into PREG (i.e., P450scc) also followed, at least at 2 months of age, this pattern. This finding, together with the observation that PREG levels were not modified in plasma, strongly suggests a specific effect of SREBP-1c on neurosteroidogenesis of the peripheral nerve. Indeed, in several experimental models, we observed that changes in plasma did not reflect changes in nervous tissues (Caruso et al. 2013; Melcangi et al. 2014 Melcangi et al. , 2016 Giatti et al. 2015) . As reported here, changes in the levels of PREG induce consequences also in the levels of its further metabolites. Indeed, either at 2 or 10 months of age, the levels of the first metabolite of PREG (i.e., PROG) are decreased, while the further metabolites of PROG are differently modulated depending on the aging of the animals. Indeed, at 2 months of age, the levels of 5a-DHP were significantly lower in sciatic nerve of SREBP-1c KO mice, while at 10 months of age the levels of 3a,5a-THP (i.e., the metabolite of 5a-DHP) were reported to be significantly higher than in WT animals. The high levels of 3a,5a-THP observed in the sciatic nerve of SREBP-1c KO mice at 10 months of age were in agreement with the high gene expression of the enzyme 3a-HSOR, which converts 5a-DHP into 3a,5a-THP. The levels of the other metabolite of 5a-DHP (i.e., 3b,5a-THP) were significantly lower and higher at 2 and 10 months of age, respectively. With the exception of T levels, we did not report changes in the levels of the androgens evaluated here. Indeed, at 2 months of age the levels of this neuroactive steroid were higher in sciatic nerve of SREBP-1c KO mice than in WT animals. However, at variance to what observed in case of PREG and PROG levels, this effect is not a peculiarity of sciatic nerve but occurred also in plasma. However, at 2 months of age the levels of a metabolite of T, such as 17b-E, are also significantly higher in sciatic nerve of SREBP-1c KO mice than in WT animals, without any variation in plasma levels. We previously demonstrated that, at 2 months of age, SREBP-1c KO mice begin to show the first signs of peripheral neuropathy (i.e., impairment of thermal and mechanical nociceptive threshold, subtle abnormalities of small unmyelinated C fibers), but only at 10 months of age this became evident with abnormal nerve conduction velocity, intraepidermal nerve fiber density, decreased g-ratio of small-caliber fibers indicating a selective hypermyelination . On this point of view, the increase of the first step of neurosteroidogenesis (i.e., the high levels of PREG as well as the high gene expression of P450scc observed in the in sciatic nerve of SREBP-1c KO mice at 2 months of age) as well as the high levels of T and its metabolite, 17b-E, might be interpreted like a possible endogenous response to the first signs of peripheral neuropathy. In agreement with this concept, it is important to highlight that, after peripheral nerve injury, the expression of translocator protein 18 kDa (i.e., a molecule involved in the translocation of cholesterol into mitochondria where the enzyme P450scc is located and consequently related to the first step of neurosteroidogenesis) is transiently up-regulated (Girard et al. 2012) . In addition, neuropathic pain (i.e., an important component of peripheral neuropathy) has also an important impact on neurosteroidogenesis with a transient up-regulation of the PREG levels (Patte-Mensah et al. 2014) .
The high levels of neuroactive steroids as a response to the first signs of peripheral neuropathy might be interpreted like a mechanism for coping with neurodegeneration. Indeed, neuroactive steroids exert a variety of protective effects on peripheral neuropathy (Melcangi et al. , 2005 Giatti et al. 2015) . For instance, PREG has been reported to counteract the decrease of the amounts of myelin membranes induced by cryolesion in sciatic nerve (Koenig et al. 1995) as well as to increase, in guided regeneration of the rabbit facial nerve, the number and g-ratio of myelinated nerve Fig. 4 Gene expression of P450 side chain cleavage (P450scc), 5a-reductase (5a-R), and 3a-hydroxysteroid oxidoreductase (3a-HSOR) in sciatic nerve of wild type (WT) and of sterol regulatory-binding protein-1c (SREBP-1c) knock-out (KO) mice at 2 and 10 months of age. Data (n = 5 for each experimental group) are expressed as relative mRNA expression AE SEM. The effects of age, genotype, and their interaction have been analyzed using the two-way ANOVA: *p < 0.05 and **p < 0.01 (see table) , followed by Bonferroni post-test: *p < 0.05 and **p < 0.01 versus WT (see histogram).
fibers (Chavez-Delgado et al. 2005) . In addition, 17b-E or T treatment promotes a faster recovery after nerve crush injury (Islamov et al. 2002; Huppenbauer et al. 2005) .
At 10 months of age (i.e., when peripheral neuropathy was ascertained) we reported two different patterns of neuroactive steroid levels in the sciatic nerve of SREBP-1c KO mice. Thus, we found low levels of neuroactive steroids, such as PREG and PROG, and high levels of PROG metabolites (i.e., 3a,5a-THP and 3b,5a-THP).
SREBP-1c KO sciatic nerve at 10 months of age experience energy depletion and mitochondrial dysfunction from a metabolic point of view . In this regard, it is important to underline that Schwann cells and neurons rely on glycolysis as fuel source. The lack of SREBP-1c imposes both cells to use fatty acid instead of glucose and lactate ; a driver toward mitochondrial dysfunction in sciatic nerve of SREBP-1c null mice. On this basis, it might be possible that at 2 months of age, when subtle signs of peripheral neuropathy are present and the metabolic switch is still not dramatic, mitochondria try to counteract the initial neurodegeneration by inducing P450scc expression, the first enzyme regulating the whole neurosteroidogenesis, and consequently the levels of its product PREG. On the contrary, at 10 months of age, mitochondria are boosted to their maximum capacity to cope with the energy depletion because of the metabolic switch from glucose toward fatty acid utilization. At this age, the lower levels of PREG were probably as a result of altered mitochondrial function. Indeed, Schwann cells' mitochondrial dysfunction is intimately associated with peripheral neuropathy development (Ino and Iino 2017) . To compensate this altered mitochondrial function, SREBP-1c KO sciatic nerve increased both 5a-R and 3a-HSOR expression levels and relative metabolites. Indeed, as extensively reported also PROG derivatives are effective in protecting peripheral nerve by aging damage , physical injury (Melcangi et al. 2000; Chavez-Delgado et al. 2005; Roglio et al. 2008) , and diabetic peripheral neuropathy (Veiga et al. 2006; Leonelli et al. 2007; Cermenati et al. 2012; Mitro et al. 2014) . In this context, it is important to highlight that differing from its precursor, 5a-DHP, which binds to PROG receptor, the further metabolites 3a,5a-THP, and 3b,5a-THP modulate the activity of GABA-A receptor . In particular, 3a,5a-THP binds and activates GABA-A receptor (Lambert et al. 2003 (Lambert et al. , 2009 Belelli and Lambert 2005) , while 3b,5a-THP, albeit unable to bind GABA-A receptor, antagonizes the effect of 3a,5a-THP . Thus, in addition to classical steroid receptor also GABA-A receptor might be considered as a possible therapeutic approach for peripheral neuropathy.
The SREBP-1c null mice shows also alteration in peripheral nerve FA composition . Here, we also shed the light on an altered neuroactive steroid pattern in both 2 and 10-month-old animals developing peripheral neuropathy. These data along with our previous observations, in which we showed that diabetes altered FA composition and 5a-DHP treatment was able to bring it back to control levels , strongly hint to a tight cross-talk between fatty acid and neuroactive steroid pathways.
In conclusion, our data suggest that during the development of peripheral neuropathy because of the blunted FA biosynthesis, neuroactive steroids at the beginning of the pathology (2 months of age) try to counteract the early stages of neurodegeneration. During the progression to peripheral neuropathy (10 months of age), when the peripheral nerve boosts mitochondria to cope energy depletion as a result of reduced glycolysis, the levels of mitochondria-produced hormone such as PREG are decreased and downstream neuroactive steroids are instead increased. These data further support the idea that neuroactive steroids, by a cross-talk with FA biosynthetic pathway, may represent a possible therapeutic strategy for peripheral neuropathy.
